. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging.
TNFϪ mice) and Lepr db mice treated with the NF-B inhibitor MG-132 showed decreased NAD(P)H oxidase activity and iNOS expression as well as elevated eNOS expression, whereas m-Lepr db mice treated with TNF-␣ showed the opposite effects. Thus, resveratrol protects against cardiac dysfunction by inhibiting oxidative/nitrative stress and improving NO availability. This improvement is due to the role of resveratrol in inhibiting TNF-␣-induced NF-B activation, therefore subsequently inhibiting the expression and activation of NAD(P)H oxidase and iNOS as well as increasing eNOS expression in type 2 diabetes. cardiac diabetic complication; antioxidants and free radicals; antiinflammation; nitric oxide; magnetic resonance spectroscopy DIABETES is associated with an excessive cardiovascular morbidity and mortality. Diabetes is an independent risk factor for left ventricular (LV) dysfunction (17) . Although one frequently associates cardiac dysfunction with enhanced coronary atherosclerosis in diabetic patients, evidence has accumulated for the existence of a specific "diabetic" cardiomyopathy, which has been shown even in the absence of hypertension and atherosclerosis in diabetic patients (47) . The relative pathogenic significance of multiple factors that may alter myocardial performance in diabetic patients awaits further delineation (22) . Furthermore, such delineation will aid in the discovery of effective therapies for diabetes-induced myocardial dysfunction.
Epidemiological studies (8, 18) have indicated that the Mediterranean diet is associated with a reduced risk of cardiovascular disease. Resveratrol is an important dietary constituent in the Mediterranean diet (37) . Previous studies have revealed that resveratrol exerts cardioprotective effects in fructose-fed rat (21) and rats with streptozotocin-induced type 1 diabetes (41) . However, the effects and mechanisms by which resveratrol protects against cardiac dysfunction in type 2 diabetes await elucidation.
MRI is a noninvasive technique that can assess both the systolic and diastolic function of the heart in vivo. Using this method, we aimed to assess cardiac function in control m-Lepr db and diabetic Lepr db mice treated with either resveratrol or vehicle. We hypothesized that resveratrol rescues cardiac dysfunction in type 2 diabetes by attenuating oxidative/nitrative stress as well as improving nitric oxide (NO) availability. To test this, we examined the effects of resveratrol on the production of NO, ROS, and reactive nitrogen species (RNS) in the cardiac tissue of Lepr db mice. We also investigated the effects of resveratrol on TNF-␣-mediated NF-B activation and the downstream signaling that contributes to the oxidative/nitrative stress and impaired NO availability to elucidate the mechanisms of resveratrol's cardioprotective effects in type 2 diabetes.
METHODS

Animals and Treatments
Experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Missouri- (34, 49) .
In Vivo Cine MRI
Noninvasive MRI scans were performed on age-matched mLepr db and Lepr db mice with or without 4 wk of resveratrol treatment using a Varian 7-T horizontal-bore MRI (Varian, Palo Alto, CA) instrument equipped with a 38-and 60-mm quadraturedriven birdcage radiofrequency coil. ECG and respiratory monitoring and gating were done with a small animal monitoring system (SA Instruments, Stony Brook, NY). Warm air was circulated through the MRI bore to maintain the animal's body temperature. Induction of anesthesia was accomplished with 4% isoflurane and 1 l/min oxygen. The respiratory rate was monitored and used to manually calibrate the maintenance dose of isoflurane at 1.2-1.8%. Imaging protocols were similar to previously published procedures (42) . Briefly, ECG/respiratory gated gradient echo sequences were acquired with 1-mm slice thickness and a 30 ϫ 30-mm 2 field of view for both long-and short-axis images. Wall thickness measurements were determined with Image J (NIH, Bethesda, MD) on the midventricular axial image immediately after the R wave and with averaging of 3 measurements/mouse. Ventricular length was determined on long-axis coronal images. LV mass (LVM) was derived from the sum of the differences between the epicardial and endocardial areas at the end of the diastolic phase from the apex to the base multiplied by slice thickness (1 mm) and the density of the myocardium (1.053 g/ml) (31) . LV end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV) were calculated as the sum of the endocardial areas of each slice from the apex to the mitral annulus plane at end diastole and end systole, respectively. LV ejection fraction (EF) was calculated as follows: LV EF ϭ (LVEDV Ϫ LVESV)/LVEDV. Stroke volume (SV) was calculated as follows: SV ϭ LVEDV Ϫ LVESV, and cardiac output (CO) was calculated as follows: CO ϭ SV ϫ HR, where HR is heart rate (44, 46) . LV volume-time curves were plotted as LV volumes versus time in one cardiac cycle. The systolic peak ejection rate (PER) and diastolic peak filling rate (PFR) were defined as the maximal absolute value of the minimum and maximum derivatives of the LV volume-time curve, respectively. Image analysis was performed using VNMRJ (Varian), Image J (http://rsb.info.nih.gov/ ij/), and Segment (http://segment.heiberg.se) (15) software tools. Protein expressions were detected using TNF-␣, IB-␣, and phospho-IB-␣ primary antibodies (Santa Cruz Biotechnology), NF-B, inducible NO synthase (iNOS), and nitrotyrosine (N-Tyr) primary antibodies (Abcam), and endothelial NO synthase (eNOS) and gp91 phox primary antibodies (BD Science Pharmingen). Signals were scanned densitometrically using Fuji LAS3000 and quantified with Multigauge software (Fujifilm). The relative amounts of protein expression were quantified to those of the corresponding m-Lepr db control, which were set to a value of 1.0.
NAD(P)H Oxidase Activity
NAD(P)H oxidase activity was assayed in homogenized heart tissue extracts using a lucigenin (Sigma)-derived chemiluminescence assay as previous described (11, 49) . Samples were read by Fluoroscan Ascent FL (Thermal Scientific), and NAD(P)H oxidase activity was normalized to the m-Lepr db control.
Immunofluorescence Staining
Immunohistochemistry was used to identify and localize gp91 phox proteins in sections of vessels or myocardial tissue. Formalin-fixed hearts were sectioned at 5 m. Primary antibodies to gp91 phox (BD Biosciences Pharmingen), the endothelial cell marker von Willebrand factor (Abcam), the smooth muscle marker ␣-actin (Abcam), or the macrophage marker F4/80 (Serotec) were used for sequential double-immunofluorescence staining. Secondary fluorescent antibodies were either FITC or Texas red conjugated. Sections were mounted in an anti-fading agent (Slowfade gold with 4=,6-diamidino-2-phenylindole, Invitrogen). Slides were observed and analyzed using a fluorescence microscope with a ϫ40 objective (Zeiss Axioplan Microscope).
Measurement of O 2 ·Ϫ Using Electron Paramagnetic Resonance Spectroscopy
O2
·Ϫ quantification from the electron paramagnetic resonance (EPR) spectra was determined in the heart tissue homogenate as previously described (48) . In brief, a 10% tissue homogenate was prepared in 50 mmmol/l phosphate buffer containing 0.01 mmol/l EDTA. The supernatants containing 2 mmol/l 1-hydroxy-3-carboxypyrrolidine were incubated for 30 min at 37°C and quickly frozen in liquid nitrogen. Superoxide quantification from the EPR spectra was determined by double integration of the peaks, with reference to a standard curve generated from horseradish peroxidase generation of the anion from standard solutions of hydrogen peroxide, using p-acetamidophenol as the cosubstrate, and then normalized by protein concentration.
Measurement of Nitrite/Nitrate
Nitrite/nitrate levels in cardiac tissue were assessed using amerometric sensors (World Precision Instruments) as reported by Zhang et al. (49) . Briefly, nitrate was converted to nitrite using Nitralyzer (World Precision Instruments). The currents (in pA) detected by the 2-mm sensor (ISO-NOP) represent the concentration of nitrite in the lysis of LV cardiac tissue.
Data Analysis
Results are reported as means Ϯ SD except as specifically stated. Data were analyzed by one-way ANOVA followed by a least-significant-difference post hoc test. Significance was accepted at P Ͻ 0.05.
RESULTS
Effects of Resveratrol on Diabetes-Induced Cardiac Dysfunction
Morpholometric parameters. LVM was lower in Lepr db mice, although there was no statistical difference. However, the LVM-to-body mass ratio was significantly lower in Lepr db mice. Resveratrol had no effect on LVM and the LVM-to-body mass ratio (Table 1) .
HR and respiratory rate. Lepr db mice had lower HRs compared with m-Lepr db mice, although the respiratory rate was similar among groups. Resveratrol did not affect HR or respiratory rate in both Lepr db and m-Lepr db mice (Table 1) . Systolic function parameters. LVEDV, LVESV, and SV were marginally decreased in Lepr db mice. CO was significantly diminished in Lepr db versus m-Lepr db mice. Resveratrol slightly increased LVEDV, LVESV, SV, and CO, although there were no statistical differences (Table 1) . EF was comparable among all groups (Table 1) .
LV volume-time curves and diastolic relaxation. LV volume-time curves indicated that PER and PFR were reduced in Lepr db mice. Resveratrol greatly increased PFR without significantly affecting PER (Table 1 and Fig. 1 ).
Resveratrol Attenuated Protein and mRNA Expression of TNF-␣ and Protein Expression of Phospho-IB-␣ and NF-B p65 in Type 2 Diabetes
Protein and mRNA expression of TNF-␣ ( 
Resveratrol Increased eNOS Expression and Nitrite/Nitrate Levels in Type 2 Diabetic Mice
Cardiac nitrite/nitrate levels were reduced in diabetic mice, and resveratrol enhanced NO production (Fig. 4A) . eNOS protein expression was downregulated in diabetic mice. Resveratrol increased eNOS expression (Fig. 4B) and mRNA expression in Lepr db mice. In contrast, protein expression of p22 phox and p67 phox showed no significant differences among groups (data not shown). Markers for endothelial cells (von Willebrand factor), vascular smooth muscle cells (␣-actin), or macrophages (F4/80) along with gp91
phox to establish the cell type expressing gp91 phox suggested that gp91 phox was localized in endothelial cells and macrophages in heart tissue (Fig. 6C) .
Resveratrol Downregulated Protein Expression of iNOS and N-Tyr in Type 2 Diabetes
Western Blot analysis (Fig. 7A) (Fig. 7B) .
DISCUSSION
The major finding of this study is that resveratrol is cardioprotective in mice with diabetic cardiomyopathy. Cardiomyopathy in this model is manifested as impaired diastolic relaxation measured by a reduction in the early filling phase of diastole. In addition, during systole, we measured reduced peak ejection. Despite reduced PER, LV EF was not impaired. We found that the resveratrol-treated diabetic mice showed lower levels of oxidative/nitrative stress with an improvement of NO availability. This suggests that the mechanisms responsible for the improvement in LV diastolic relaxation with resveratrol were due to the inhibition of oxidative/nitrative stress and improvement of NO availability in this model (Fig. 8) .
Cardioprotective Effects of Resveratrol in Type 2 Diabetes
The cardioprotective effects of resveratrol have been studied in various disease models. Echocardiographic analyses showed that resveratrol reduced isovolumic relaxation time, a parameter of diastolic function, in aging (3) and pressure overload-induced cardiac hypertrophy (aortic banded rat model) (16) . In a rat model of myocardial ischemia-reperfusion injury, in vivo LV catheterization showed that resveratrol pretreatment increased LV maximum systolic pressures and dP/dt max and decreased myocardial infarct size (35) . Using in vivo MRI, we demonstrated that resveratrol improved cardiac function in type 2 diabetic mice. The results suggested that at 16 wk old, although SV was only marginally decreased in male Lepr db mice, CO was significantly diminished (Table 1 and Fig. 1 ). Both PER and PFR were significantly lower in Lepr db mice, suggesting the early impairment of systolic and diastolic function. Systolic dysfunction is more likely dependent on the degree of myocyte loss and myocyte injury, which account for reduced contractility, decreased pump function, and EF (10). Resveratrol did not exhibit significant benefits in improving SV, CO, or PER, but greatly increased PFR (Table 1 and Fig. 1) . Therefore, we posit that resveratrol exerts a beneficial role in diabetic cardiomyopathy mainly by improving diastolic function. Although resveratrol prevented dietinduced obesity and alleviated insulin resistance in high-fat diet-fed mice and streptozotocin-induced type 1 diabetic rats, in Lepr db mice, resveratrol did not alter body weight or reduce hyperinsulinemic hyperglycemia (49) . Thus, the therapeutic effects of resveratrol, especially on cardiac dysfunction, can also occur independently of weight loss and hyperglycemic status.
Furthermore, Lepr db mice had a lower LVM-to-body mass ratio compared with m-Lepr db mice (Table 1) . These results are consistent with a previous investigation of hearts using MRI in type 2 diabetic mice by Panagia et al. (28) . Although resveratrol improved diastolic function, it showed no marked effect via a morphological change of the heart in both m-Lepr db and Lepr db mice. Therefore, early intervention by resveratrol supplementation might be a promising approach to prevent or delay the onset of diabetic cardiomyopathy. 
Resveratrol Reduced Cardiac TNF-␣ Expression and NF-B Activation
Resveratrol inhibited TNF-␣ production by the LPS-activated brain macrophage, the microglia (4). It also abrogated cigarette smoking-induced upregulation of TNF-␣ in rat carotid arteries (7) . We demonstrated that TNF-␣ mRNA and protein expression were elevated in type 2 diabetic mouse cardiac tissue and that resveratrol inhibited TNF-␣ expression in type 2 diabetes (Fig. 2) . The TNF-␣ inhibitory effects of resveratrol may contribute to its cardioprotective benefits since TNF-␣ has been shown to be a prognostic marker in patients with heart failure. Etanercept, a soluble TNF-␣ receptor antagonist, attenuated LV dilatation and restored EF in progressive LV dysfunction in a pacing-induced heart failure dog model (23) . There is a controversial role of TNF-␣ antagonists in the clinical treatment of heart failure. A clinical study (20) has shown a lack of benefits of anti-TNF-␣ treatment in patients with chronic heart failure in a multicenter, randomized, placebocontrolled clinical trial. Despite these findings, further investigation is needed to determine if individualized dosing of anti-TNF-␣ therapy will exhibit beneficial effects by treating patients with early-stage cardiac dysfunction before any final conclusions can be made (24) .
Resveratrol not only inhibits TNF-␣ expression but also inhibits NF-B activation. Our study suggests that total IB-␣ expression was decreased in Lepr db mice, whereas IB-␣ phosphorylation and NF-B p65 expression were elevated (Fig. 3) . Resveratrol inhibited phospho-IB-␣ and NFB p65 expression without affecting total IB-␣ expression in Lepr db mice (Fig. 3) . These results suggest that resveratrol inhibits NF-B activation by preventing the phosphorylation of IB-␣, therefore abolishing the downstream signaling induced by NF-B activation.
Effects of Resveratrol on NO Production and eNOS Expression
Agonist-stimulated release of NO from eNOS in the coronary endothelium exerts paracrine effects on cardiomyocytes, predominantly affecting the timing of relaxation as well as myocardial O 2 consumption (32). The autocrine role of eNOS within cardiomyocytes may include the modulation of basal inotropy and relaxation, ␤-adrenergic responsiveness, and the force-frequency relationship (32) . eNOS Ϫ/Ϫ mice are not only hypertensive but also characterized by enhanced systolic function and depressed diastolic function without LV hypertrophy (30) . Moreover, inhibition of basal NO production by the NOS inhibitor N G -monomethyl-L-arginine significantly impaired LV diastolic filling (6) . This suggests that NO derived from eNOS contributes to myocardial relaxation (29) .
In a pressure overload-induced cardiac hypertrophy rat model, eNOS and redox factor-1 expression were significantly reduced. Resveratrol increased eNOS and redox factor-1 expression and improved diastolic relaxation (16) . Our results suggest that resveratrol at a dose of 20 mg·kg Ϫ1 ·day Ϫ1 increased eNOS protein expression in Lepr db mice (Fig. 4B) , which was associated with enhanced myocardial nitrite/nitrate levels, a parameter of NO production (Fig. 4A) . Furthermore, db TNFϪ /db TNFϪ and Lepr db mice treated with MG-132 exhibited elevated eNOS protein expression, whereas eNOS expression was reduced in m-Lepr db mice with recombinant TNF-␣ treatment (Fig. 4B) , suggesting that resveratrol may affect eNOS expression by inhibiting TNF-␣-NF-B signaling. Thus, resveratrol's benefits in improving cardiac filling of diabetic mice may ameliorate cardiomyopathy by enhancing eNOSderived NO production.
Effects of Resveratrol on NAD(P)H Oxidase Subunit Expression, NAD(P)H Oxidase Activation, and Subsequent O 2 ·Ϫ Production
NO production by eNOS does not accurately reflect NO availability since inactivation of NO by ROS is recognized to be a key mechanism underlying reduced NO bioavailability (5). A previous study (36) suggested that LV diastolic function is correlated with oxidative stress. Therefore, we evaluated oxidative stress in cardiac tissue of diabetic mice. Despite the presence of multiple ROS sources, studies (13, 14) in the last decade have indicated that the major cardiovascular source of ROS, particularly in the vasculature, originates from a family of NADPH oxidases. Our previous studies (11, 12) have indicated that db TNFϪ / db TNFϪ and MG-132-treated Lepr db mice exhibit reduced NAD(P)H oxidase activity in coronary arterioles. The present study showed that NAD(P)H oxidase activity was elevated in the cardiac tissue of Lepr db mice, whereas db TNFϪ /db TNFϪ and MG132-treated Lepr db mice revealed ameliorated NAD(P)H oxidase activation (Fig. 5B) . O 2 ·Ϫ production was elevated in Lepr db mice, and the NAD(P)H oxidase inhibitor apocynin reduced O 2 ·Ϫ production back to the level of the m-Lepr db control, suggesting that NAD(P)H oxidase may be one of the main sources of O 2 ·Ϫ production in diabetic mouse cardiac tissue (Fig. 5A) . Resveratrol inhibited NAD(P)H oxidase activity and subsequent O 2 ·Ϫ production, possibly by inhibiting TNF-␣-induced NF-B activation.
The classical NADPH oxidase complex comprises membrane-bound cytochrome b558 (composed of one gp91 phox subunit and one p22 phox subunit), which forms the catalytic core of the enzyme, and four cytosolic regulatory subunits (p47 phox , p67 phox , p40 phox , and Rac) (19) . gp91 phox is one of the most important subunits in NAD(P)H oxidase-mediated oxidative stress since deletion of gp91 phox severely inhibits activated O 2 ·Ϫ production (1). We determined that gp91 phox protein and mRNA expression were elevated in diabetic mice (Fig. 6, A  and B phox is mainly colocalized with endothelial cells and macrophages in cardiac tissue (Fig. 6C) . Thus, the antioxidative effects may contribute to the cardioprotective effects by resveratrol via LV relaxation.
Effects of Resveratrol on iNOS Expression and Subsequent Nitrative Stress
iNOS is induced by inflammatory cytokines and produces a much higher level of NO compared with constitutive NOS (43) . Cardiac myocytes, as well as a number of other parenchymal cells within the myocardium, including the endothelium of the coronary microvasculature, endocardium, and infiltrating inflammatory cells, are all able to express iNOS in response to soluble inflammatory mediators (2) . A recent study (43) demonstrated that pathological concentrations of NO produced by iNOS may result in nitrative stress and tissue injury by generating the powerful nitrative molecule peroxynitrite (ONOO Ϫ ). A transgenic mouse model conditionally targeting the expression of human iNOS cDNA to the myocardium displayed upregulation of iNOS, which led to an increased production of ONOO Ϫ . Those mice infrequently developed overt heart failure but displayed a high incidence of sudden cardiac death due to bradyarrhythmia (25) . Myocardial reperfusion injury increased iNOS expression and subsequent generation of RNS (N-Tyr), which was prevented by pretreatment with 1400W, a selective iNOS inhibitor, or M-40401, an ONOO Ϫ scavenger (39) . Thus, nitrative stress and peroxynitrite play a crucial role in the pathogenesis of diabetic cardiomyopathy (26, 27 inhibitor 1400W reversed the increased N-Tyr expression, suggesting a role for iNOS in the increased RNS production in the diabetic cardiomyocyte (Fig. 7A) . Therefore, we postulate that the effects of resveratrol on reducing cardiac N-Tyr expression might be partially explained by its role in inhibiting iNOS expression (Fig. 7B) . Although iNOS expression was increased in the cardiac tissue of diabetic mice versus control mice, iNOS protein expression in aortas was not different between control and diabetic mice (data not shown). Moreover, 50-kDa N-Tyr protein expression was over 10 times higher in the heart of diabetic mice compared with control mice, whereas it was only 3 times higher in the aorta of diabetic mice versus control mice (49) , supporting the view of more marked nitrative stress in the cardiac tissue of type 2 diabetic mice. NF-B activation is required for TNF-␣-induced iNOS gene expression in both human liver (AKN-1) and human lung (A549) epithelial cell lines (40 (Fig. 7B ). These findings suggest that TNF-␣-induced NF-B activation may upregulate iNOS expression in diabetic mouse cardiac tissue.
Resveratrol Regulates the Imbalance of NO and O 2 ·Ϫ in Type 2 Diabetes
A complex paracrine interaction exists between endothelial cells and cardiac myocytes in the heart. Cardiac endothelial cells release (or metabolize) several diffusible agents that exert direct effects on myocyte function, independent of changes in coronary flow (33) . The role of NO in this paracrine/autocrine pathway is active due to the short diffusion distance between cardiac microvessel endothelial cells and ventricular cardiomyocyte (Ͻ1 m) (38) . In pathological situations, the beneficial effects of NO resulting from eNOS-derived NO were diminished by either reduced production or enhanced inactivation by ROS. There can also be deleterious effects of NO that result from excessive NO production by iNOS, usually with concurrent ROS production and ONOO Ϫ formation (33) . Thus, the balance between NO and ROS production is a major factor in the pathophysiological state of the cardiovasculature.
Resveratrol inhibits NAD(P)H oxidase-derived O 2 ·Ϫ as well as iNOS-derived NO but stimulates eNOS-derived NO production. This prevents cardiac oxidative/nitrative stress and improves NO availability. Therefore, by regulating the imbalance between NO and ROS, resveratrol is postulated to be efficient in ameliorating oxidative/nitrative stress and subsequent tissue damage in the diabetic heart.
Conclusions
In conclusion, MRI assessment of cardiac function in diabetic mice supports the existence of diabetic cardiomyopathy in this animal model of type 2 diabetes. Reduced systolic function and abnormal diastolic function were evident in 16-wk-old diabetic mice. Importantly, systolic and diastolic dysfunction in the diabetic hearts were not associated with cardiac hypertrophy because the measured wall thickness (data not shown) and calculated LVM were not increased (Table 1) . This alteration coexisted with enhanced TNF-␣ expression, NF-B activation, and NF-B downstream signaling, which contributed to the perpetuation of oxidative/nitrative stress as well as decreased NO availability. Our results in resveratrol-treated Lepr db mice showed normalized diastolic function, suggesting that pharmacological interventions to promote NO availability and suppress oxidative/nitrative stress may reduce diabetesinduced cardiac dysfunction. We suggest that resveratrol has a potential role as a novel pharmacological agent in restoring cardiac function during the early stages of diabetic cardiomyopathy.
